The drug repurposing industry has become a critical focus within pharmaceutical innovation, driven by the need to optimize existing compounds to accelerate therapeutic developments. This dynamic industry is witnessing increasing investment and strategic initiatives from leading market players, highlighting its growing relevance in effective drug development cycles and healthcare solutions.

Market Size and Overview

The Global Drug Repurposing Market size is estimated to be valued at USD 36.69 billion in 2026 and is expected to reach USD 49.59 billion by 2033, exhibiting a compound annual growth rate (CAGR) of 4.4% from 2026 to 2033.

 Drug Repurposing Market Growth reflects expanding market opportunities driven by regulatory support, technological advancements, and an increasing emphasis on cost-effective drug development strategies in the pharmaceutical sector. The market report showcases robust industry trends favoring faster approval timelines and reduced R&D costs, reshaping the drug discovery landscape globally.

Market Segments
The Drug Repurposing Market can be segmented into based on drug type, therapeutic application, and end-user categories:

- Drug Type: Small molecules and biologics; small molecules dominate due to ease of repositioning and regulatory acceptance, while biologics represent the fastest-growing sub-segment propelled by innovation in monoclonal antibodies and gene therapies as evidenced by recent launches in 2024.
- Therapeutic Application: Oncology, cardiovascular diseases, neurological disorders; oncology remains the dominant segment due to a high volume of clinical repurposing trials recorded in 2025, with neurological disorders emerging as the fastest-growing area owing to breakthrough repurposed drugs addressing unmet patient needs.
- End User: Pharmaceutical companies, biotechnology firms, research institutes; pharmaceutical companies retain dominance in drug repurposing investments, whereas biotechnology firms show the fastest growth fueled by cutting-edge drug repositioning platforms introduced in 2024.

Market Drivers
A pivotal market driver accelerating drug repurposing revenue is the rising regulatory encouragement for repurposed drugs. The U.S. FDA and EMA have introduced frameworks in 2024 that streamline approval pathways for repurposed candidates, significantly reducing time to market. Coupled with the escalating pressure to curtail exorbitant R&D costs, these regulatory advances have opened substantial market opportunities. For instance, data from 2024 highlights a 30% decrease in approval time for certain repurposed drugs, directly contributing to industry growth and market dynamics.

Segment Analysis – Therapeutic Application
Within the therapeutic application segment, oncology leads in market revenue due to a high prevalence of drug resistance and relapse challenges, encouraging repurposing research. For example, several kinase inhibitors originally developed for one cancer type found renewed use in others, yielding over USD 5 billion in revenue for industry players in 2025. Additionally, neurological disorders represent the fastest-growing sub-segment, underpinned by recent case studies where repurposed anti-inflammatory drugs demonstrated efficacy in neurodegenerative disease trials concluded in 2024. This segment’s expansion reflects evolving market trends favoring treatment innovation for chronic conditions with limited new drug pipelines.

Consumer Behaviour Insights
Recent surveys from 2024–2025 reveal three striking shifts in stakeholder preferences within the drug repurposing market:
1. Increased adoption of digital platforms for data mining and AI-driven drug repositioning, reflecting a shift towards technology-enabled discovery. According to a 2025 report, 65% of pharmaceutical buyers now prefer partners with robust digital repurposing capabilities.
2. Heightened sensitivity to cost efficiency, with contract research organizations reporting a 20% rise in requests for drug repurposing projects over de novo drug development, emphasizing budget-conscious strategies.
3. Growing demand for customized therapeutic solutions, particularly in oncology and rare diseases, pushing companies to focus on tailored repurposing approaches supported by patient data analytics and real-world evidence gathered between 2024 and 2025.

Key Players
Leading market companies actively shaping the drug repurposing landscape include Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, AstraZeneca PLC, and Eli Lilly. In 2024, Pfizer expanded its drug repurposing portfolio by acquiring AI-centric biotech firms, enhancing pipeline diversification. AstraZeneca invested in capacity expansion to support collaborative repurposing trials for respiratory diseases, resulting in significant operational scalability. Furthermore, Eli Lilly launched several novel repurposed therapies targeting neurological disorders in 2025, achieving an uptick in market revenue and positioning itself strongly against emerging market rivals. Such market growth strategies illustrate the evolving competitive landscape and the increasing emphasis on innovation and collaboration.

Key Winning Strategies Adopted by Key Players
Among distinctive market growth strategies, Pfizer’s 2025 integration of AI-guided drug repurposing stands out, shortening early phase identification cycles by 40% and boosting revenue growth substantially. Similarly, Novartis’s partnership with academic institutions to fund repurposing trials for rare diseases in 2024 enhanced its research productivity and expanded its product pipeline. Another impactful strategy is Bristol-Myers Squibb’s deployment of patient-centered data platforms in 2025, aligning drug repositioning efforts with personalized medicine demands, which improved trial success rates by over 15%. These actionable strategies offer valuable lessons on harnessing innovation and collaboration to accelerate growth within the drug repurposing market.

Frequently Asked Questions (FAQs)

1. Who are the dominant players in the Drug Repurposing Market?
Key market players include Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, AstraZeneca PLC, and Eli Lilly, each engaged in strategic product launches and expansions between 2024 and 2025.

2. What will be the size of the Drug Repurposing Market in the coming years?
The drug repurposing market size is forecasted to grow from USD 36.69 billion in 2026 to USD 49.59 billion by 2033, reflecting a CAGR of approximately 4.4%.

3. Which end-user industry has the largest growth opportunity?
Pharmaceutical companies currently dominate, but biotechnology firms exhibit the fastest growth due to advancements in innovative drug repositioning technologies.

4. How will market development trends evolve over the next five years?
Market trends emphasize AI-driven repurposing methods, regulatory support fostering faster drug approvals, and increased emphasis on personalized medicine models—shaping the future industry scope.

5. What is the nature of the competitive landscape and challenges in the Drug Repurposing Market?
The landscape is highly dynamic, with challenges including intellectual property complexities and regulatory hurdles. However, collaborative models and digital innovation are mitigating these restraints.

6. What go-to-market strategies are commonly adopted in the Drug Repurposing Market?
Strategies include acquiring technology-driven biotechs, academic partnerships for clinical trials, and leveraging patient data platforms for personalized drug repositioning.

Get More Insights on Drug Repurposing Market

Get This Report in Japanese Language - 医薬品用途転換市場

Get This Report in Korean Language - 약물 재창출 시장

Read More Articles Related to this Industry –

Nanofiber Applications in Medical Devices: Revolutionizing Healthcare

Camera Modules in Medical Devices: Revolutionizing Diagnostics and Treatment

About Author: 

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.